Andrew Arno - 15 Aug 2022 Form 4 Insider Report for Oncocyte Corp (OCX)

Role: Director
Signature: /s/ Andrew Arno
Issuer symbol: OCX
Transactions as of: 15 Aug 2022
Net transactions value: +$144,121
Form type: 4
Filing time: 17 Aug 2022, 20:15:36 UTC
Previous filing: 19 Jul 2022
Next filing: 22 Aug 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	OCX	Common Stock, no par value	Award	$0	+10,000	+8.2%	$0.000000	132,049	15 Aug 2022	Direct	F1
transaction	OCX	Common Stock, no par value	Purchase	$32,064	+34,477	+26%	$0.9300	166,526	15 Aug 2022	Direct	F2
transaction	OCX	Common Stock, no par value	Purchase	$112,057	+115,523	+69%	$0.9700	282,049	16 Aug 2022	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	OCX	Option to Purchase Common Stock	Award	$0	+45,000		$0.000000	45,000	15 Aug 2022	Common Stock	45,000	$0.9700	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Restricted Stock Units shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders.
F2	The price of $0.93 per share represents a weighted average of prices ranging from $0.90 to $0.95 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3	The price of $0.97 per share represents a weighted average of prices ranging from $0.93 to $1.00 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4	Options shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders.